In supplemental Table 3, in the second of the 3 column subheadings under “Relapsed/Refractory” and “Total,” “160 mg qd” should read “160 mg bid.” In supplemental Table 5, row 7, “TEAE” should read “treatment-related TEAE.” The corrected supplemental data file has been placed in the online version of the article.
. 2021 Feb 25;137(8):1131. doi: 10.1182/blood.2021010665
Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037.
© 2021 by The American Society of Hematology
This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC8555385 PMID: 33630056
This corrects the article "Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up" in volume 136 on page 2027.